Shandong Weigao Group Medical Polymer Co (1066) AI Stock Analysis

• Market Cap: HK$16.87B
• Dividend Yield: 4.58%
• Average Volume (3M): 10.92M
• Price to Earnings (P/E): 13.0
• Beta (1Y): 1.08
• Revenue Growth: 0.74%
• EPS Growth: 2.13%
• Country: HK
• Employees: 12,719
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.15
• Shares Outstanding: 4,522,332,500
• 10 Day Avg. Volume: 7,849,305
• 30 Day Avg. Volume: 10,915,466
• PEG Ratio: 2.08
• Price to Book (P/B): 0.82
• Price to Sales (P/S): 1.49
• P/FCF Ratio: 8.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.48
• Price Target Upside: 16.76% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.48
• Revenue Forecast (FY): HK$14.64B

• Rating: 68 Neutral
• Price Target: HK$5.50 ▼(-0.90% Downside)
• Action: Reiterated Date: 10/14/25
• Date: Action: Reiterated 10/14/25

The stock's overall score is primarily driven by its strong valuation, with an attractive P/E ratio and dividend yield. Financial performance is solid, but concerns about revenue decline and cash flow management slightly dampen the outlook. Technical analysis suggests weak market momentum, which is a risk factor.

Positive Factors

High Profitability

Sustained high gross and healthy net margins indicate durable pricing power and efficient cost structure in core polymer medical consumables. This profitability supports internal reinvestment, dividend capacity and resilience to cost shocks over the medium term.

Negative Factors

Slight Revenue Decline

A falling top line, even if modest, erodes operating leverage and constrains capacity to expand margins or invest in growth. If sustained, revenue decline could force margin trade-offs or limit the company's ability to scale R&D and commercial efforts over months.

Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model

Company Description

Shandong Weigao Group Medical Polymer Co., Ltd. is a leading Chinese manufacturer specializing in the production of medical devices and polymer products. Established in 1992, the company operates primarily in the healthcare sector, offering a dive...

Read more

Shandong Weigao Group Medical Polymer Co., Ltd. is a leading Chinese manufacturer specializing in the production of medical devices and polymer products. Established in 1992, the company operates primarily in the healthcare sector, offering a dive...

How the Company Makes Money

Shandong Weigao Group generates revenue through the sale of its medical devices and consumables, which are essential for healthcare facilities. The company has established a comprehensive revenue model that includes direct sales to hospitals and h...

Read more

Shandong Weigao Group generates revenue through the sale of its medical devices and consumables, which are essential for healthcare facilities. The company has established a comprehensive revenue model that includes direct sales to hospitals and h...

Shandong Weigao Group Medical Polymer Co Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.10B	13.09B	13.23B	13.62B	13.15B	11.62B
Gross Profit	6.46B	6.58B	6.64B	7.31B	7.35B	6.46B
EBITDA	3.08B	3.14B	3.55B	4.38B	3.75B	3.09B
Net Income	1.97B	2.07B	2.00B	2.76B	2.28B	2.09B
Balance Sheet
Total Assets	36.14B	34.76B	33.67B	33.20B	30.37B	27.34B
Cash, Cash Equivalents and Short-Term Investments	9.65B	8.32B	7.33B	7.49B	7.13B	6.14B
Total Debt	5.51B	4.19B	4.17B	4.49B	4.14B	4.32B
Total Liabilities	10.45B	9.42B	9.68B	9.75B	9.46B	8.95B
Stockholders Equity	24.10B	23.75B	22.45B	21.67B	19.27B	17.55B
Cash Flow
Free Cash Flow	2.05B	2.19B	2.11B	1.10B	1.92B	1.70B
Operating Cash Flow	2.65B	2.79B	2.80B	2.21B	3.04B	2.70B
Investing Cash Flow	-2.21B	-1.10B	-1.39B	-2.57B	-1.48B	423.22M
Financing Cash Flow	-500.93M	-1.60B	-2.16B	-1.02B	-547.92M	-1.79B

Shandong Weigao Group Medical Polymer Co Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1066, the sentiment is Negative. The current price of 5.55 is above the 20-day moving average (MA) of 4.53, above the 50-day MA of 4.90, and below the 200-day MA of 5.59, indicating a bearish trend. The MACD of -0.31 indicates Positive momentum. The RSI at 24.89 is Positive, neither overbought nor oversold. The STOCH value of 8.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1066.

Shandong Weigao Group Medical Polymer Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1358	74 Outperform	HK$1.59B	6.78	3.68%	7.46%	21.39%	-0.57%
3600	74 Outperform	HK$5.73B	8.36	16.76%	3.65%	6.87%	18.37%
1501	73 Outperform	HK$7.21B	20.75	11.20%	―	14.06%	3.02%
2276	72 Outperform	HK$21.54B	14.57	24.01%	0.63%	13.58%	24.59%
1066	68 Neutral	HK$16.87B	13.02	6.64%	4.58%	0.74%	2.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Shandong Weigao Group Medical Polymer Co Corporate Events